A 58-year-old man presents with painless jaundice, weight loss, and imaging confirms unresectable locally advanced pancreatic adenocarcinoma. He has adequate performance status (ECOG 0). What is the drug of choice for first-line chemotherapy in this setting?

Explanation

## First-Line Chemotherapy for Unresectable Pancreatic Cancer **Key Point:** FOLFIRINOX is the preferred first-line regimen for fit patients with locally advanced or metastatic pancreatic adenocarcinoma, offering superior overall survival compared to gemcitabine monotherapy. ### Evidence Base The ACCORD-11 trial demonstrated that FOLFIRINOX significantly improves median overall survival (11.1 months vs 6.8 months with gemcitabine alone) in patients with good performance status, despite higher toxicity. ### Regimen Characteristics | Feature | FOLFIRINOX | Gemcitabine | Nab-Paclitaxel + Gemcitabine | |---------|-----------|------------|---------------------------| | **Median OS** | 11.1 months | 6.8 months | 8.5 months | | **Response Rate** | 31.6% | 9.4% | 23% | | **Grade 3–4 Toxicity** | 66% | 44% | 40% | | **Suitable for** | ECOG 0–1, fit patients | Elderly/frail patients | Intermediate fitness | | **Regimen Intensity** | High | Low | Intermediate | **High-Yield:** FOLFIRINOX is the **gold standard** for fit patients with unresectable pancreatic cancer. Gemcitabine + nab-paclitaxel is an alternative for patients who cannot tolerate FOLFIRINOX. ### Patient Selection for FOLFIRINOX 1. ECOG performance status 0–1 2. Adequate organ function (hepatic, renal, cardiac) 3. Age typically < 75 years (relative, not absolute) 4. Willing to accept higher toxicity for survival benefit **Clinical Pearl:** Patients with ECOG 2 or significant comorbidities should receive gemcitabine monotherapy or gemcitabine + nab-paclitaxel instead, as FOLFIRINOX toxicity may outweigh benefit. **Warning:** Do not confuse FOLFIRINOX with single-agent chemotherapy — it is a combination regimen requiring careful monitoring for neutropenia, neuropathy, and diarrhea.